Neurofibromatosis

1) Disease Description (Causes and Symptoms)

• Definition summary: Neuroblastoma is a malignant tumor in children that originates in the sympathetic nervous system (mainly the adrenal medulla or the paraspinal sympathetic ganglia), and is one of the most common childhood cancers in infants. At diagnosis, most cases occur in children younger than 2 years, and it is rare after age 10.
• Causes/pathophysiology:
  • No single clear cause is known. Reports have linked it to chromosomal abnormalities (e.g., abnormalities of the short arm of chromosome 1 and those associated with Turner syndrome).
  • Some environmental exposures (such as prenatal exposure to anticonvulsants) have been suggested as risk factors.
  • Genetic predispositions of tumor cells (e.g., MYCN amplification) have a major impact on tumor biology and prognosis.
  • If the tumor secretes catecholamines (hormone-like substances), it can cause systemic symptoms (tachycardia, sweating, facial flushing, hypertension, etc.).
• Main symptoms (symptoms according to the site of occurrence and metastasis):
  • Abdominal tumor: abdominal mass (palpable), abdominal distension, weight loss, swelling of the lower extremities and scrotum (due to compression of veins and lymphatic vessels)
  • Chest/neck tumor: facial swelling, difficulty breathing, symptoms of superior vena cava syndrome
  • Paraspinal lesion: weakness or paralysis of the lower extremities, urinary or bowel dysfunction
  • Metastasis (including to the bones): bone pain, limping
  • Systemic/endocrine symptoms: tachycardia, sweating, facial flushing, unstable body temperature, uncontrolled diarrhea, etc.
• Other: Some neonatal neuroblastomas may spontaneously regress (spontaneous remission).

2) Treatment Methods and Precautions

• Care approach:
  • A multidisciplinary (pediatric oncology, surgery, radiation oncology, nuclear medicine, etc.) treatment plan is established according to the stage and risk level (age, stage, degree of tumor-cell differentiation, MYCN status, etc.).
• Standard treatments (by risk level and condition):
  • Surgery: Radical resection is performed when possible. In the case of an abdominal mass, diagnosis and treatment may be performed simultaneously during surgery.
  • Chemotherapy: Used depending on the extent of disease, from localized to systemic disease. Neoadjuvant chemotherapy may be used to shrink the tumor and make surgery possible.
  • Radiation therapy: Used when residual disease remains or local control is needed.
  • Autologous hematopoietic stem cell transplantation (after high-dose chemotherapy): Used for reconstruction in high-risk patients.
  • Immunotherapy and targeted therapy: Anti-GD2 antibodies (e.g., dinutuximab) and maintenance therapy (such as retinoids) contribute to improving treatment outcomes in high-risk patients. If an ALK mutation or other relevant finding is identified, targeted drugs, including clinical trials, may be considered.
  • MIBG therapy (radioiodinated MIBG): May be used to treat recurrent or refractory MIBG-positive tumors.
• Diagnostic and monitoring tests:
  • Measuring tumor markers such as urinary VMA/HVA and serum NSE is useful for diagnosis and follow-up.
  • Staging is determined using CT/MRI, MIBG scans, bone scans, bone marrow examinations, and other tests.
• Precautions during and after treatment (including self-care):
  • Increased risk of infection during chemotherapy (visit a medical institution immediately if fever occurs).
  • Changes in blood pressure and heart rate caused by catecholamine secretion (monitoring is necessary).
  • Management and long-term follow-up are necessary for long-term effects of anticancer drugs and radiation (growth delay, endocrine abnormalities, hearing impairment, effects on fertility, etc.).
  • Monitor for postoperative complications (such as bleeding and organ damage).
• Risk of complications:
  • Permanent neurological damage due to spinal cord compression, extensive metastasis (to the bones and bone marrow), treatment-related toxicity (bone marrow suppression and organ toxicity), recurrence, etc.

3) Points to Check Before an Outpatient Visit (Including Examples of Items to Prepare and Records)

• Items to bring and prepare:
  • A complete list of medications currently being taken (including prescription drugs, nonprescription drugs, and supplements)
  • Copies of previous test results (pathology reports, CT/MRI, MIBG/bone marrow examinations, blood and urine tests, etc.)
  • Records of recent changes in weight and food intake, and a symptom diary (fever, pain, changes in urination/bowel movements, difficulty breathing, etc.)
  • Family history (cancer and genetic diseases) and exposure history related to pregnancy and childbirth, if possible
  • Emergency contact information and documents verifying the identity of the guardian
  • Insurance and medical-care-related documents, if needed
• Information to check in advance at the outpatient visit (recording is recommended):
  • The time symptoms began and how they have progressed (changes in mass size, pain, swelling, etc.)
  • Whether acute symptoms such as fever, bleeding, diarrhea, or vomiting are present
  • Recent vaccination history and possible exposure to infection
  • Whether fertility preservation is desired (for adolescents)

4) Examples of General Questions to Ask the Doctor

• "What is this patient's stage, and how are they classified by risk (low, intermediate, or high risk)?"
• "What treatment options do you recommend (surgery/chemotherapy/radiation/transplantation/immunotherapy), and what are the advantages and disadvantages of each?"
• "What are the main side effects expected during treatment, and how should they be managed?"
• "How likely are long-term complications from treatment (such as effects on growth, hearing, and fertility)? What is the prevention and monitoring plan?"
• "Is participation in a clinical trial or targeted treatment (e.g., ALK-targeted therapy, MIBG therapy, or anti-GD2 immunotherapy) possible?"

5) Examples of Disease-Specific Questions

• "How does the presence or absence of MYCN amplification in the tumor affect the treatment plan (intensity and type of treatment)?"
• "How is it determined whether the tumor is MIBG-positive, and how likely is MIBG therapy (radioiodine therapy) to be applicable?"